We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from Insulet (PODD - Free Report) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $518.5 million, representing an increase of 19.8% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Insulet metrics that are commonly monitored and projected by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- Total Omnipod' will likely reach $514.73 million. The estimate suggests a change of +22% year over year.
According to the collective judgment of analysts, 'Revenue- Drug Delivery' should come in at $3.28 million. The estimate points to a change of -69.4% from the year-ago quarter.
Analysts expect 'Revenue- International Omnipod' to come in at $123.11 million. The estimate suggests a change of +21.4% year over year.
Analysts forecast 'Revenue- U.S. Omnipod' to reach $391.62 million. The estimate indicates a change of +22.2% from the prior-year quarter.
Insulet shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #2 (Buy), PODD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Insulet (PODD - Free Report) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $518.5 million, representing an increase of 19.8% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Insulet metrics that are commonly monitored and projected by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- Total Omnipod' will likely reach $514.73 million. The estimate suggests a change of +22% year over year.
According to the collective judgment of analysts, 'Revenue- Drug Delivery' should come in at $3.28 million. The estimate points to a change of -69.4% from the year-ago quarter.
Analysts expect 'Revenue- International Omnipod' to come in at $123.11 million. The estimate suggests a change of +21.4% year over year.
Analysts forecast 'Revenue- U.S. Omnipod' to reach $391.62 million. The estimate indicates a change of +22.2% from the prior-year quarter.
View all Key Company Metrics for Insulet here>>>
Insulet shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #2 (Buy), PODD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>